Scienion and Axela to work together
Targets markets include oncology, autoimmune, allergy, immunoassay, infectious disease and others.
It will provide commercialization partners with a scalable offering to address emerging diagnostic markets, said the firms.
Paul Smith, president of Axela, said its printing requirements are unique in that it services many markets, requiring production of a variety of chips.
“These typically contain between 10-150 targets drawn from a diverse selection of antigens, antibodies and oligonucleotide probes.
“A precise and versatile liquid handling technology was necessary to meet these demanding requirements, while still providing our partners with a robust, go to market production solution.”
Scienion is a developer of ultra-low volume liquid handling technology and Axela’s technology platform is based on proprietary flow through arrays for molecular diagnostics that allow multiplex detection of nucleic acids and proteins.
Holger Eickhoff, founder and CEO of Scienion, said the Axela system is designed for real-world applications and the agreement is a testament to ongoing efforts to expand.
“At the same time, we look forward to utilizing our extensive experience in diagnostics markets to help Axela expand its business opportunities. This partnership with Axela allows Scienion to better position itself in the diagnostics eco-system, supplying unique solutions to these markets.”